(NASDAQ: TVTX) Travere Therapeutics's forecast annual revenue growth rate of 33.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.75%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.42%.
Travere Therapeutics's revenue in 2026 is $591,331,000.On average, 16 Wall Street analysts forecast TVTX's revenue for 2026 to be $69,395,951,179, with the lowest TVTX revenue forecast at $58,626,622,561, and the highest TVTX revenue forecast at $79,837,251,232. On average, 16 Wall Street analysts forecast TVTX's revenue for 2027 to be $103,027,362,626, with the lowest TVTX revenue forecast at $81,537,721,152, and the highest TVTX revenue forecast at $130,080,293,160.
In 2028, TVTX is forecast to generate $130,928,642,898 in revenue, with the lowest revenue forecast at $97,937,264,198 and the highest revenue forecast at $154,305,391,234.